VRTX Stock Analysis 2026: CF Franchise, CASGEVY, JOURNAVX, Pipeline and Valuation
Summary Vertex Pharmaceuticals enters the second half of 2026 with a strong cystic fibrosis franchise, growing contributions from ALYFTREK, CASGEVY and JOURNAVX, a potentially valuable kidney-disease
2026-07-28